Key facts
- This page summarizes Eugene Bauer's Form 4 filing for Evommune, Inc. (EVMN).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 17 Nov 2026, 16:37.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Disposed to Issuer
Award
Disposed to Issuer
Award
Additional SEC filing notes
Footnote F1
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on December 8, 2025.
Footnote F2
The transaction reported herein reflects a one-time stock option repricing (the "Option Repricing") pursuant to which the exercise price of the reported option has been amended to reduce the exercise price to $7.63 per share. If the Reporting Person exercises this option prior to the earliest of: (i) November 13, 2027; (ii) a Change in Control, as defined in the Issuer's 2025 Equity Incentive Plan (the "2025 Plan"); and (iii) the Reporting Person's death or Disability or termination of employment by the Issuer without Cause (each as defined in the 2025 Plan) or resignation following a Change in Control for Good Reason (as defined in the Reporting Person's employment agreement, if applicable), then the Reporting Person will be required to pay a premium exercise price equal to the original exercise price per share of such option.
Footnote F3
One fourth (1/4) of the shares subject to the option award shall vest on December 8, 2026 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Footnote F4
The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on April 16, 2026.
Footnote F5
One fourth (1/4) of the shares subject to the option award shall vest on April 16, 2027 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.